Kymera Therapeutics Inc (KYMR)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Fiscal Year End Date: 12/31
| 06-2022 | 03-2022 | 12-2021 | 09-2021 | 06-2021 | |
| Sales | 11,514 | 9,622 | 15,275 | 20,336 | 18,519 |
| Gross Profit | 11,514 | 9,622 | 15,275 | 20,336 | 18,519 |
| Operating Expenses | 52,324 | 46,555 | 49,269 | 48,973 | 43,249 |
| Operating Income | -40,810 | -36,933 | -33,994 | -28,637 | -24,730 |
| Interest Expense | 41 | 41 | 53 | 70 | 28 |
| Other Income | 594 | 290 | 147 | 125 | 98 |
| Pre-tax Income | -40,257 | -36,684 | -33,900 | -28,582 | -24,660 |
| Net Income Continuous | -40,257 | -36,684 | -33,900 | -28,582 | -24,660 |
| Net Income | $-40,257 | $-36,684 | $-33,900 | $-28,582 | $-24,660 |
| EPS Basic Total Ops | -0.78 | -0.71 | -0.69 | -0.56 | -0.55 |
| EPS Basic Continuous Ops | -0.78 | -0.71 | -0.69 | -0.56 | -0.55 |
| EPS Diluted Total Ops | -0.78 | -0.71 | -0.69 | -0.56 | -0.55 |
| EPS Diluted Continuous Ops | -0.78 | -0.71 | -0.69 | -0.56 | -0.55 |
| EBITDA(a) | $-39,428 | $-35,071 | $-31,669 | $-26,306 | $-22,946 |